Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT01024387Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2010
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ganitumab in Carcinoid Tumor (CT), Pancreatic neuroendocrine tumor (PanNET), sponsored by Dana-Farber Cancer Institute. Started Mar 2010; status: completed.
02
Drugs
ganitumab
03
Conditions
Carcinoid Tumor (CT)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01024387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024387.